Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Coloplast A/S    COLO B   DK0060448595

COLOPLAST A/S (COLO B)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
The feature you requested does not exist. However, we suggest the following feature:

Coloplast A/S : Patent Issued for Method of Dissecting Tissue (USPTO 9937320)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/19/2018 | 05:53pm CEST

By a News Reporter-Staff News Editor at Biotech Week -- From Alexandria, Virginia, NewsRx journalists report that a patent by the inventors Daniel, Geoffrey A. (Crystal, MN); El-Hage, Fernando (Brooklyn Park, MN); Poucher, Neal (North Oaks, MN), filed on March 18, 2016, was published online on April 10, 2018 (see also Coloplast A/S).

The patent's assignee for patent number 9937320 is Coloplast A/S (Humlebaek, DK).

News editors obtained the following quote from the background information supplied by the inventors: "Urinary incontinence affects about 200 million people worldwide and about 25 million people in the US. Urinary incontinence in women can be associated with a prolapse of one or more pelvic organs, which can arise from a weakness in the tissues/muscle of the pelvic floor. Urinary incontinence in men can arise after surgical treatment of the prostate glade, which treatment can include removal or weakening of the prostatic sphincter associated with the urinary urethra.

"One treatment for urinary incontinence includes placing an artificial sphincter around a circumference of a portion of the urethra. The artificial sphincter operates to compress the urethra to selectively coapt or stop the flow of urine through the urethra, thus providing the user with a continent state. The artificial sphincter can be activated to an open position by the user, which opens the urethra and allows the user to selectively pass urine.

"Surgeons and patients would welcome advances in the treatment of urinary incontinence."

As a supplement to the background information on this patent, NewsRx correspondents also obtained the inventors' summary information for this patent: "One aspect provides a surgical system adapted for dissection of tissue around an organ or around a lumen. The surgical system includes a tissue dissection tool and a catheter. The tissue dissection tool includes a shaft connected between a handle and a tissue dissection head. At least the tissue dissection head of the tissue dissection tool is magnetized to a first polarity. The catheter is insertable into the organ or the lumen, with a wall of the catheter magnetized to the first polarity. When the catheter is inserted into the organ or the lumen, the first polarity of the catheter is configured to repel the first polarity of the tissue dissection head of the tool away from the catheter and away from in the urethra."

For additional information on this patent, see: Daniel, Geoffrey A.; El-Hage, Fernando; Poucher, Neal. Method of Dissecting Tissue. U.S. Patent Number 9937320, filed March 18, 2016, and published online on April 10, 2018. Patent URL: http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=9937320.PN.&OS=PN/9937320RS=PN/9937320

Keywords for this news article include: Biotechnology, Biomedical Engineering, Biomedicine, Europe, Denmark, Business, Coloplast A/S, Bioengineering, Health and Medicine, Urinary Incontinence, Artificial Sphincters, Urologic Diseases and Conditions.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2018, NewsRx LLC

(c) 2018 NewsRx LLC, source Health Newsletters

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on COLOPLAST A/S
04/19COLOPLAST A/S : Patent Issued for Method of Dissecting Tissue (USPTO 9937320)
AQ
04/16COLOPLAST A/S : Share buy-back week 15/2018
AQ
04/10GLOBAL MACROMOLECULE HYDROGEL MARKET : 99strategy.biz added a depth and professi..
AQ
04/09COLOPLAST A/S : Share buy-back week 14/2018
AQ
04/06COLOPLAST A/S : expands its product portfolio with new innovative ostomy categor..
AQ
04/05COLOPLAST A/S : Patent Issued for Access Sheath (USPTO 9925357)
AQ
04/03COLOPLAST A/S : Share buy-back week 13/2018
AQ
03/26COLOPLAST A/S : Share buy-back week 12/2018
AQ
03/22COLOPLAST A/S : Patent Issued for Wound Dressing (USPTO 9913759)
AQ
03/19COLOPLAST A/S : Share buy-back week 11/2018
AQ
More news
News from SeekingAlpha
02/01Coloplast ASB 2018 Q2 - Results - Earnings Call Slides 
02/01Coloplast ASB reports Q1 results 
2017Coloplast (CLPBF) Presents At Berenberg European Corporate Conference - Slide.. 
2017Coloplast (CLPBY) Presents At DbAccess Pharmaceutical & Healthcare Corporate .. 
2017Coloplast AS ADR 2017 Q4 - Results - Earnings Call Slides 
Financials ( DKK)
Sales 2018 16 461 M
EBIT 2018 5 100 M
Net income 2018 3 936 M
Debt 2018 1 228 M
Yield 2018 2,87%
P/E ratio 2018 27,95
P/E ratio 2019 25,96
EV / Sales 2018 6,34x
EV / Sales 2019 5,88x
Capitalization 103 B
Chart COLOPLAST A/S
Duration : Period :
Coloplast A/S Technical Analysis Chart | COLO B | DK0060448595 | 4-Traders
Technical analysis trends COLOPLAST A/S
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 20
Average target price 508  DKK
Spread / Average Target -2,6%
EPS Revisions
Managers
NameTitle
Lars Søren Rasmussen President & Chief Executive Officer
Michael Pram Rasmussen Chairman
Allan Rasmussen Executive Vice President-Global Operations
Anders Lonning-Skovgaard Chief Financial Officer & Executive Vice President
Oliver Johansen Senior VP-Global Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
COLOPLAST A/S5.57%17 023
HENRY SCHEIN-0.19%10 658
CANTEL MEDICAL CORP.12.02%4 832
AMPLIFON SPA23.83%4 422
MERIT MEDICAL SYSTEMS, INC.5.56%2 312
PATTERSON COMPANIES-38.20%2 113